Agenda
*Date and Time: 17/6/2021, 19:00 - 20:30 CEST
Welcome, Introduction, Polling Questions
The Current Role of BTK Inhibitors in CLL – Dr. Ghia
A Focus on Safety of BTK inhibitors in the Management of CLL – Dr. Follows
Practical Case Discussions: Selecting BTK inhibitor Therapy in CLL – Dr. LeBlond
Audience Q&A
Summary and Final Thoughts
Events
Date / Time
Event Details
Faculty
Program Director
Paolo Ghia, MD
Professor of Medical Oncology
Università Vita-Salute San Raffaele
Milano, Italy
Faculty
George A. Follows, MD, PhD
Consultant Haematologist
Visiting Professor of Haematology
Anglia Ruskin Medical School
Associate Lecturer
University of Cambridge, U.K.
Faculty
Veronique Leblond, MD
Head of the Department of Hematology
Pitié Salpêtrière Hospital
Paris, France
Goal Statement
The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize the use of current and emerging therapeutic strategies with BTK inhibitors in the care of their patients with chronic lymphocytic leukemia.
Target Audience
This program is intended for global hematologists, oncologists and other clinicians involved in the management of patients using BTK inhibitors in the treatment of patients with CLL.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Evaluate differences between first- and next-generation BTK inhibitors in terms of molecular characteristics, selectivity, preclinical data, approved indications, dosing, safety profile, and efficacy
- Identify patient candidates for BTK inhibitor-based therapy, in either treatment naïve or previously treated CLL
- Select optimal BTK inhibitor-based therapy for patients with CLL, taking into consideration guidelines, expert recommendation, and recent practice-changing clinical trial results
- Recognize and manage adverse events and toxicities associated with BTK inhibitor therapy to support adherence, appropriate dosing, quality of life, and continuation of treatment
- Assess ongoing clinical trials evaluating currently available and emerging BTK inhibitors (and BTK-based combinations) to aid clinical trial enrollment and predict new options in the clinic
Accreditation
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Credit Designation
CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.